AbbVie Beats Profit Expectations Despite Losing Blockbuster Drug

Drug giant AbbVie surprised investors with strong quarterly results, even as the company continues to lose sales from its once best-selling medicine.

AbbVie is a major pharmaceutical company (a business that makes prescription drugs) that recently lost the ability to be the only seller of Humira, its blockbuster drug for treating immune system conditions. When a drug loses this protection, called patent exclusivity, cheaper copies can enter the market, causing sales to drop dramatically.

Here's what happened in their latest quarter:

• Revenue beat expectations (the company made more money than analysts predicted) • Newer drugs are filling the gap left by declining Humira sales • The company's immunology drugs (medicines that treat immune system disorders like arthritis) are performing well • Stock investors reacted positively to the news

The key takeaway is that AbbVie successfully prepared for Humira's patent loss by developing and selling other medicines. Their newer immunology drugs like Skyrizi and Rinvoq are growing fast enough to offset (make up for) the decline in Humira revenue.

This matters because it shows AbbVie can maintain its business even after losing its biggest money-maker. For investors, this suggests the company remains financially healthy and could continue growing despite this major challenge.

This is an AI-generated summary. Read the original article at: https://www.investing.com/news/stock-market-news/abbvie-tops-quarterly-expectations-as-newer-immunology-drugs-offset-humira-decline-4644659